Back to search

Article

Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma

2024-01-10

Abstract excerpt

<title>Abstract</title> <p>Background The aim of this study was to identify clinically significant biomarkers of a response to atezolizumab plus bevacizumab (ATZ + BV) therapy, and to target strategies against unresectable hepatocellular carcinoma (u-HCC). Method We first investigated the potential of circulating tumor DNA (ctDNA) to serve as a biomarker for predicting the therapeutic outcome in 24 u-HCC patien...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e48033c9-4b30-587e-9dbc-b1d5e9fecace
DOI
10.21203/rs.3.rs-3824952/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaDOI 10.21203/rs.3.rs-3824952/v1
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.Semantic proximity
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.Semantic proximity
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinomaSemantic proximity
Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patientsSemantic proximity
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.Semantic proximity
Exploring Mechanism of Action of Abemaciclib in Breast Cancer Through Circulating Chromatin FragmentSemantic proximity
Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity
Predictive model for BNT162b2 vaccine response in cancer patients based on cytokines and growth factorsSemantic proximity
Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based TreatmentSemantic proximity
Immune Characterization of Metastatic Colorectal Cancer Patients Post Reovirus AdministrationSemantic proximity
Gemcitabine plus Oxaliplatin (GEMOX) combined with Atezolizumab and Bevacizumab for Advanced Biliary Tract Cancer: A Preliminary Observational StudySemantic proximity
Circulating biomarkers in the diagnosis and management of hepatocellular carcinomaSemantic proximity
Select a neighboring publication to make it the new centre.